Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Negative Regulator Molecules01:23

Negative Regulator Molecules

35.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

27.3K
The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
27.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The diagnostic role of transbronchial lung cryobiopsy in inflammatory myeloid neoplasms.

Respiratory medicine and research·2026
Same author

Lung involvement of myeloid-lymphoid neoplasm with eosinophilia.

American journal of respiratory and critical care medicine·2025
Same author

Cluster analysis for clinical, radiological, and histopathological profiling in chronic pulmonary graft-versus-host disease.

European journal of internal medicine·2025
Same author

EBUS/EUS-guided lymph nodal gadolinium injection and MRI of the chest in diagnosis of abnormal lymphatic drainage. A case series.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2025
Same author

Indwelling pleural catheters and medical thoracoscopy.

Breathe (Sheffield, England)·2025
Same author

Bispecific T-Cell Engagers-Induced Interstitial Lung Disease: Two Case Reports Confirmed by Transbronchial Lung Cryobiopsy.

Respiration; international review of thoracic diseases·2025

相关实验视频

Updated: May 10, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.4K

"回到真相":从负面的IPF试验中学到的经验教训

Athina Trachalaki1,2, Anna L Lindahl3,2, Simone Petrarulo4,2

  • 1Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.

Breathe (Sheffield, England)
|April 21, 2025
PubMed
概括

异形性肺纤维化 (IPF) 药物开发面临挑战,因为新疗法的晚期试验如zinpentraxin alfa,ziritaxestat和pamrevlumab都失败了. 解决试验设计中的陷和采用创新的方法对于未来的IPF治疗成功至关重要.

更多相关视频

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.6K

相关实验视频

Last Updated: May 10, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.4K
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.6K

科学领域:

  • 肺部病理学 肺部病理学
  • 临床药理学 临床药理学
  • 生物统计学 生物统计学

背景情况:

  • 异形性肺纤维化 (IPF) 是一种渐进的肺病,尽管存在像皮尔芬尼和宁泰达尼布这样的疗法,但有效治疗方法有限.
  • 最近对新型IPF疗法的晚期临床试验产生了令人失望的结果,突出了药物开发中的挑战.
  • "回归真相"的现象表明,积极的早期试验结果可能并不总是转化为后期疗效.

研究的目的:

  • 检查三个关键的IPF新疗法 (zinpentraxin alfa,ziritaxestat,pamrevlumab) 的晚期临床试验,这些新疗法未能满足其主要终点.
  • 根据这些试验失败,识别IPF药物开发中的常见陷和挑战.
  • 提出创新的方法和方法来提高未来IPF临床试验的稳定性和成功率.

主要方法:

  • 对新的IPF疗法进行三项特定晚期临床试验的审查和分析.
  • 在试验设计中确定常见问题,包括样本大小,终点选择和背景治疗的整合.
  • 探索用于未来药物开发的先进的统计和试验设计方法.

主要成果:

  • 在晚期发育阶段,Zinpentraxin alfa,Ziritaxestat和pamrevlumab的试验失败了,这表明翻译有希望的早期结果存在重大障碍.
  • 发现的关键挑战包括不充分的II期样本大小,过度依赖代用终点 (如强迫生命能力),以及难以管理并发性抗纤维菌治疗.
  • 这些失败凸显了药物开发中的"回归到真相",早期的疗效信号可能无法在更大,后期的研究中得到证实.

结论:

  • 在IPF药物开发中晚期失败需要对当前的临床试验策略进行重新评估.
  • 实施适应性试验设计,贝叶斯统计和复合终点可以提高试验严格性.
  • 平台试验为加速多种IPF疗法的测试提供了潜在的途径,最终旨在改善IPF患者的治疗结果和生存率.